Status:
UNKNOWN
Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborating Sponsors:
Taipei City Hospital
Mackay Memorial Hospital
Conditions:
Metabolic Syndrome
Diabetes
Eligibility:
All Genders
18-65 years
Brief Summary
Diabetes is prevalent in schizophrenics and may be induced by antipsychotic treatments. Several retrospective studies have suggested that psychiatric patients exposed to atypical antipsychotics may be...
Detailed Description
Specific Aims Although our original interests were condensed in atypicals, the fact that some hospitals discourage the use of atypical antipsychotics for new onset schizophrenia for policy reasons di...
Eligibility Criteria
Inclusion
- Inpatients and outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria
- Treated either with typical or atypical antipsychotics
Exclusion
- Illegal drug use/abuse/dependence
- Alcoholism
- Pregnancy
- Clinical diagnosis of type I or type II diabetes before the onset of schizophrenia or treatment of schizophrenia (via chart review).
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
1350 Patients enrolled
Trial Details
Trial ID
NCT00201292
Start Date
March 1 2005
End Date
October 1 2008
Last Update
November 15 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Health-Yuli Hospital
Yuli, Hu-lien County, Taiwan, 981
2
Song-de Branch, Taipei City Hospital
Taipei, Taipei, Taiwan, 110
3
Mackay Memorial Hospital
Taipei, Taipei, Taiwan